OptiNose, Inc. (OPTN)
| Market Cap | 180.02M |
| Revenue (ttm) | 68.49M |
| Net Income (ttm) | -90.54M |
| Shares Out | 82.20M |
| EPS (ttm) | -1.71 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 407,439 |
| Open | 2.16 |
| Previous Close | 2.20 |
| Day's Range | 2.11 - 2.27 |
| 52-Week Range | 1.46 - 4.85 |
| Beta | 0.93 |
| Analysts | Strong Buy |
| Price Target | 9.20 (+320.1%) |
| Earnings Date | n/a |
About OPTN
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase 3b clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It is also d...
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for OptiNose stock is "Strong Buy." The 12-month stock price forecast is 9.20, which is an increase of 320.09% from the latest price.
News
Rising P/E: An Overlooked Trick to Land on 5 Winning Stocks
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
Optinose Announces Appointment of Two New Members to Board of Directors
YARDLEY, Pa., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced its Bo...
Optinose to Present at the Piper Sandler Virtual Healthcare Conference
YARDLEY, Pa., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that C...
OptiNose (OPTN) Sees Hammer Chart Pattern: Time to Buy?
OptiNose (OPTN) has been struggling lately, but the selling pressure may be coming to an end soon.
After Plunging 44.2% in 4 Weeks, Here's Why the Trend Might Reverse for OptiNose (OPTN)
The heavy selling pressure might have exhausted for OptiNose (OPTN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in ...
Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
YARDLEY, Pa., Nov. 18, 2021 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced ...
Optinose Announces Closing of $46.0 Million Public Offering of Common Stock
YARDLEY, Pa., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the cl...
Optinose Announces Pricing of Public Offering of Common Stock
YARDLEY, Pa., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the pr...
See Why Optinose Shares Plunged To 52-Week Low Today
ENT and allergy-focused company Optinose Inc (NASDAQ: OPTN) posted Q3 Xhance (fluticasone propionate) sales of $21.8 million, +41% Y/Y, missing the consensus of $23.48 million. The Company held cash and...
OptiNose (OPTN) Reports Q3 Loss, Lags Revenue Estimates
OptiNose (OPTN) delivered earnings and revenue surprises of 13.51% and -8.68%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Optinose Announces Proposed Public Offering of Common Stock
YARDLEY, Pa., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that i...
Optinose Reports Third Quarter 2021 Financial Results and Recent Operational Highlights
Third quarter 2021 XHANCE net revenue of $22 million increased 41% compared to third quarter 2020
Optinose Announces Reporting Date for Third Quarter 2021 Financial Results
Conference Call and Webcast to be held November 16, 2021 at 8:30 a.m. Eastern Time
Will OptiNose (OPTN) Report Negative Q3 Earnings? What You Should Know
OptiNose (OPTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Optinose Completes Patient Recruitment in Second Pivotal Trial for XHANCE in Chronic Sinusitis
Company Expects Top-Line Results in Second Quarter 2022
Optinose to Present at the Cantor Virtual Global Healthcare Conference
YARDLEY, Pa., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that ...
OptiNose (OPTN) Reports Q2 Loss, Tops Revenue Estimates
OptiNose (OPTN) delivered earnings and revenue surprises of -2.33% and 5.84%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
OptiNose: Q2 Earnings Insights
Shares of OptiNose (NASDAQ:OPTN) remained unaffected after the company reported Q2 results. Quarterly Results Earnings per share were up 21.43% year over year to ($0.44), which missed the estimate of ($...
Optinose Reports Second Quarter 2021 Financial Results and Recent Operational Highlights
Second quarter 2021 XHANCE net revenue of $18.4 million increased 79% compared to second quarter 2020
Optinose Completes Patient Recruitment in Pivotal Trial for XHANCE in Chronic Sinusitis
Company Expects Top-Line Results in First Quarter 2022
OptiNose (OPTN) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
OptiNose (OPTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Optinose Technology Inventor Per Djupesland Named Winner of European Inventor Award 2021 for Industry
Co-founder and Chief Scientific Officer of Optinose AS honored for his invention of the technology used in the Optinose Exhalation Delivery System Co-founder and Chief Scientific Officer of Optinose AS ...
Experts Issue New Treatment Algorithm for Chronic Rhinosinusitis with Nasal Polyps That Highlights Role of XHANCE® In...
YARDLEY, Pa., June 2, 2021 /PRNewswire/ -- Optinose (NASDAQ:OPTN), a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy ...
Optinose to Present at the Jefferies Virtual Healthcare Conference
YARDLEY, Pa., June 01, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that C...
OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates
OptiNose (OPTN) delivered earnings and revenue surprises of 5.77% and 4.90%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?